Background-Increased vascular superoxide anion (⅐O 2 Ϫ ) production contributes to endothelial dysfunction and hypertension in animal models of cardiovascular disease. Observations in experimental animals suggest that angiotensin II (Ang II) increases ⅐O 2 Ϫ production by activation of vascular NAD(P)H oxidase. We studied the sources of ⅐O 2 Ϫ production in human blood vessels and investigated whether, and by what mechanism, Ang II might alter vascular ⅐O 2 Ϫ production. Methods and Results-Internal mammary arteries (IMAs) and saphenous veins (SVs) were collected at the time of cardiac surgery. Vessels were incubated in Krebs buffer at 37°C. ⅐O 2 Ϫ was measured by lucigenin chemiluminescence. Basal ⅐O 2 Ϫ concentrations were greater in IMAs than SVs. Inhibitors of NAD(P)H oxidase (10 mol/L to 200 mol/L diphenyleneiodonium) and xanthine oxidase (1 mmol/L allopurinol) caused reductions in ⅐O 2 Ϫ concentrations in both IMAs and SVs. Western blotting of superoxide dismutase proteins demonstrated similar expression in IMAs and SVs. Vessels were also incubated in the presence or absence of Ang II (1 pmol/L to 1 mol/L). Ang II increased ⅐O 2 Ϫ production in IMAs at 4 hours of incubation (control, 978Ϯ117 pmol ⅐ min 
I ncreased vascular superoxide anion (⅐O 2
Ϫ ) production can lead to reduced bioavailable nitric oxide (NO) 1 and impaired endothelium-dependent relaxation, 2,3 a feature of disease states such as hypertension, 4 hypercholesterolemia, 5 diabetes, 6 and heart failure. 7 In experimental animals, the cellular sources of vascular ⅐O 2 Ϫ production in animals are the endothelium, 8 vascular smooth muscle cells (VSMCs), 9 and adventitial fibroblasts. 10 The main enzymatic sources of ⅐O 2 Ϫ production within the vascular wall are NAD(P)H oxidase, 11 xanthine oxidase, 12 and endothelial NO synthase (eNOS) enzyme. 13 Superoxide can be removed by reaction with other free radicals, such as NO, to form peroxynitrite 1 or enzymatically by superoxide dismutase (SOD) to form H 2 O 2 . 14 Three mammalian SODs exist: copper/zinc SOD (Cu/Zn-SOD), manganese SOD (Mn-SOD), and extracellular SOD (EC-SOD). Mn-SOD and Cu/Zn-SOD are major vascular isoforms and are important in both scavenging vascular ⅐O 2 Ϫ and enhancing the bioavailability of endothelial NO. 15 Further evidence from animal studies suggests that the activity of one ⅐O 2 Ϫ -producing enzyme, NAD(P)H oxidase, may be modulated by angiotensin II (Ang II) and that ⅐O 2 Ϫ , in turn, may play a role in the physiological and pathophysiological actions of this peptide. Ang II increases VSMC ⅐O 2 Ϫ production by activation of a membrane-bound NAD(P)H oxidase. 16 In rats chronically infused with pressor and nonpressor doses of Ang II, increased vascular NAD(P)H oxidase ⅐O 2 Ϫ production contributed to the development of both endothelial dysfunction and hypertension. 17 In rabbits, activation of the renin-angiotensin system also contributes to increased ⅐O 2 Ϫ production and vascular dysfunction. 18 Superoxide production has recently been measured in human arteries but not in veins. 19 The enzymatic sources of
Ϫ generation in human blood vessels, however, have not been identified. Furthermore, it is not known whether Ang II alters ⅐O 2 Ϫ production in human blood vessels. We hypothesized that angiotensin II, in addition to its known physiological and pathophysiological effects, is able to stimulate ⅐O 2 Ϫ generation in human vessels and furthermore, that this mechanism can be inhibited with a specific Ang II type 1 (AT 1 ) receptor antagonist.
Our aims in this study were first, to study the cellular and enzymatic sources of ⅐O 2 Ϫ production in human blood vessels; second, to quantify the amount of SOD protein present in arteries and veins to assess whether SOD expression might account for any differences in ⅐O 2 Ϫ measured; and finally, to investigate whether, and by what mechanism, Ang II might affect ⅐O 2 Ϫ production in human blood vessels.
Methods

Patient Characteristics
Patients with coronary artery disease (CAD) who were undergoing elective CABG were included in this study. Patient characteristics were determined by review of case records. A history of current cigarette smoking, hypertension (blood pressure Ͼ140/90 mm Hg), diabetes mellitus, and hypercholesterolemia (plasma cholesterol Ͼ200 mg/dL) were considered risk factors for CAD. Approval from the West Glasgow Hospitals University Trust Ethics Committee was granted for this study.
Vessel Preparation
Distal segments of left internal mammary artery (IMA) and saphenous vein (SV), which were harvested at the time of routine coronary artery revascularization surgery, were immediately taken to the laboratory in Krebs-HEPES buffer on ice. At this point and in these conditions, the blood vessels were then carefully dissected free of loose connective tissue, divided into 4-to 5-mm segments, and weighed. The vessels were then incubated in Krebs buffer at pH 7.4Ϯ2 and maintained in atmospheric conditions (PO 2 19Ϯ4 kPa; PCO 2 3Ϯ4 kPa) at 37°C.
Measurement of Superoxide Anion Production
Vascular ⅐O 2 Ϫ was measured by lucigenin-enhanced chemiluminescence in a liquid scintillation counter (Hewlett Packard model Tricarb 2100TR) as previously described 8, 12 and recently revalidated by Li et al. 20 Absolute counts were quantified with a xanthine/ xanthine oxidase calibration curve for ⅐O 2 Ϫ generation and reported as pmol ⅐ min Ϫ1 ⅐ mg tissue Ϫ1 . In all experiments, ⅐O 2 Ϫ production was measured in paired samples with a matched control from the same vessel in every case.
Effect of Varying Lucigenin Concentrations on ⅐O 2 Production
Lucigenin itself has been reported to generate ⅐O 2 Ϫ at higher concentrations. 21 Therefore, a range of lucigenin concentrations was used to assay ⅐O 2 Ϫ in a series of samples from single vessels by use of xanthine/xanthine oxidase calibration curves with the appropriate concentration of lucigenin in each sample. Superoxide production in IMA was similar, with a lucigenin concentration of either 5 mol/L (1715Ϯ343 pmol ⅐ min
; nϭ6, Pϭ0.59). In SV, sufficient tissue was available to assess the effect of lucigenin on ⅐O 2 Ϫ production at lucigenin concentrations of 5 to 250 mol/L. Superoxide production was 311Ϯ67 pmol ⅐ min
with 50 mol/L lucigenin, and 241Ϯ50 pmol ⅐ min Ϫ1 ⅐ mg Ϫ1 with 250 mol/L lucigenin (nϭ10 for each lucigenin concentration; PϭNS between all groups). These data show that ⅐O 2 Ϫ production in IMA and SV was not affected by the concentration of lucigenin under these conditions. Ϫ . In addition, some vessels were denuded of endothelium by rubbing. The absence of the endothelium and the integrity of the vessel wall were confirmed by histological analysis in a subset of 20 vessels. Vessels were also incubated in the absence (control) or presence of 1 pmol/L, 1 nmol/L, and 1 mol/L of Ang II for 1 and 4 hours. Functional integrity of the vessels was not compromised by this incubation. IMA tissues were also incubated with 1 mol/L of Ang II for 15 minutes. To assess the effects of a positive control, IMAs were incubated in the absence or presence of norepinephrine 1 mol/L for 4 hours. In addition, IMAs were coincubated with 1 mol/L of Ang II and either an AT 1 -specific and competitive receptor antagonist (losartan, 1 mol/L) or a nonspecific receptor antagonist (sar 1 , thre 8 Ang II, 1 mol/L). 
Experimental Design
Western Blotting
Five-millimeter segments of vessels were homogenized in 200 L of a boiling vanadate buffer. After centrifugation at 14 000g for 60 seconds, the supernatant was withdrawn and the protein concentration measured. Ten micrograms of protein and prestained molecular weight standards were separated by SDS-PAGE with a 12% gel. The proteins were transferred overnight onto a polyvinylidene difluoride membrane and sequentially probed with sheep monoclonal antiCuZn-SOD or rabbit polyclonal anti-Mn-SOD or anti-actin antibodies. Protein bands were visualized by enhanced chemiluminescence (GS-525 Biorad-Laboratories Ltd).
Organ Bath Studies
Studies of the isometric tension development of isolated IMA and SV rings were performed by methods previously described. 3 Ang II dose-response curves (10 pmol/L to 100 nmol/L) were performed in the presence and absence of 10 mol/L losartan and 10 mol/L [sar 1 , thre 8 ]-Ang II.
Materials
Xanthine, xanthine oxidase, lucigenin, DETCA, Tiron, DPI, L-NAME, ALP, [sar 1 , thre 8 ]-Ang II, and norepinephrine were purchased from Sigma-Aldrich. Losartan was obtained as a gift from Merck, Sharp & Dohme (UK). DPI and ALP were dissolved in DMSO, and all other drugs were dissolved in buffer. For studies with DPI and ALP, the appropriate concentration of DMSO was added to control samples. Anti-Mn-SOD was a gift from Professor Taniguchi (University of Osaka, Japan) and anti-CuZn-SOD was purchased from Calbiochem.
Statistical Analyses
All data are presented as meanϮSEM or as percent change from controls to facilitate comparison between groups. Statistical analyses of vascular ⅐O 2 Ϫ concentrations were undertaken by use of the Wilcoxon signed-rank test. The relationships between risk factors and basal vascular ⅐O 2 Ϫ concentrations were determined by use of the Pearson correlation coefficient (r). A value of PϽ0.05 was considered statistically significant.
Results
Patient Characteristics
The study population consisted of 244 consecutive patients with CAD who underwent CABG in our hospital over a 14-month period. Data on age, sex, risk factors, and drug therapy are given in Table 1 . Patient age ranged from 33 to 80 years. Seventy-five percent of patients had Ն1 risk factors for CHD, and 92% of patients were on Ն1 types of antianginal therapy.
Basal ⅐O 2 ؊ Production in Human Arteries and Veins
Superoxide production was greater in human arteries than in veins: 
Characterization of ⅐O 2 ؊ Production
The free radical scavenger Tiron (10 mmol/L) reduced basal ⅐O 2 Ϫ concentrations in both IMA (control, 1937Ϯ412; Tiron, 10 mmol/L 901Ϯ94; nϭ9, Pϭ0.018; 95% CI, Ϫ1919, Ϫ238) and SV (control, 350Ϯ85; Tiron 10 mmol/L, 149Ϯ39; nϭ13, Pϭ0.002; 95% CI, Ϫ311, Ϫ95). DETCA (100 mol/L), an inhibitor of SOD, increased ⅐O 2 Ϫ steady-state concentrations in IMA (control, 853Ϯ208; DETCA 100 mol/L, 1492Ϯ347; nϭ8, Pϭ0.021; 95% CI, 186, 1149) and SV (control, 551Ϯ145; DETCA 100 mol/L, 945Ϯ245; nϭ14, Pϭ0.002; 95% CI, 67, 694). The NAD(P)H oxidase inhibitor DPI (concentration range, 10 to 200 mol/L) attenuated ⅐O 2 Ϫ generation in both arteries (Table 2 ) and veins ( Table 3 ). The xanthine oxidase inhibitor ALP (1 mmol/L) attenuated ⅐O 2 Ϫ production in both IMA and SV (Tables 2 and 3 ). The effects on ⅐O 2 Ϫ steady-state concentrations in IMA and SV of endothelial denudation by rubbing and inhibition of eNOS by incubation with L-NAME were more variable (Tables 2 and 3) . Incubation of IMA with L-NAME (100 mol/L) and endothelial denudation reduced ⅐O 2 Ϫ concentrations in 7 of 10 and 6 of 10 patients, respectively. In SV, these treatments corresponded to a reduction in ⅐O 2 Ϫ concentrations in 12 of 16 and 10 of 14 patients. Sufficient tissue was available in veins to study the effects of L-NAME treatment and endothelium removal by rubbing in vessel segments from the same patients. In these studies, both manipulations had similar effects on ⅐O 2 Ϫ concentrations in individual patients (rϭ0.85, nϭ12, PϽ0.001). Furthermore, the difference in ⅐O 2 Ϫ concentrations between IMA and SV was maintained after both endothelial denudation and eNOS inhibition.
Quantification of SOD Proteins
Immunoblotting showed that single bands were detected for both Mn-SOD and CuZn-SOD (Figure 2 ). The intensity of 
Effect of Ang II on ⅐O 2 ؊ Production
Ang II at concentrations of 1 mol/L, 1 nmol/L, and 1 pmol/L increased ⅐O 2 Ϫ production in IMA but not SV ( Figure  3 , Table 4 ). In IMA, Ang II had no effect on ⅐O 2 Ϫ production after 15 minutes of incubation (control, 1173Ϯ239 pmol ⅐ min Ϫ1 ⅐ mg tissue
; nϭ11, Pϭ0.12; 95% CI, Ϫ680, 155) but increased ⅐O 2 Ϫ production after 1 and 4 hours, respectively. Norepinephrine (1 mol/L), which was used as a positive control, had no effect on ⅐O ; nϭ7, Pϭ0.18; 95% CI, Ϫ391, 45).
Losartan (1 mol/L), a competitive AT 1 -specific receptor antagonist, had no effect on basal ⅐O 2 Ϫ production but blocked the Ang II-mediated increase of ⅐O 2 Ϫ production ( Figure 4 
; nϭ15, Pϭ0.63; 95% CI, Ϫ200, 305). Isometric tension studies in IMA rings confirmed that both antagonists were effective in blocking Ang II-induced vasoconstriction. Incubation of IMA for 4 hours with DPI 100 mol/L, but not DPI 10 mol/L, blocked Ang II-mediated increase of ⅐O 2 Ϫ production ( Figure 5 ).
Discussion
We have shown that basal ⅐O 2 Ϫ concentrations are greater in human IMA than SV and have demonstrated that both NAD(P)H oxidase and xanthine oxidase enzymes contribute to basal ⅐O 2 Ϫ production in these vessels. Furthermore, we report that SOD proteins are quantitatively similar in human IMA and SV. This is the first demonstration that Ang II can increase ⅐O 2 Ϫ production in human arteries. This effect is AT 1 receptor-dependent, as it was completely blocked by an AT 1 receptor antagonist. We have also demonstrated that this Ang II-mediated increase of ⅐O 2 Ϫ is mediated by NAD(P)H oxidase, as it was inhibited by DPI. This is a clinically important observation, as physiological concentrations (pmol) of Ang II induced an increase in ⅐O 2 Ϫ production in human arteries, and this effect was blocked by losartan.
In the present study, the higher basal ⅐O 2 Ϫ concentrations in arteries, compared with those in veins, were maintained after endothelial denudation by rubbing. This suggests that VSMCs may be an important source of ⅐O 2 Ϫ generation, as arteries have a proportionately greater content of VSMCs than veins. The balance between ⅐O 2 Ϫ generation and degra- DPI, ALP, and L-NAME are inhibitors of NAD(P)H oxidase, xanthine oxidase, and eNOS enzymes, respectively. Data are shown as meanϮSEM. dation determines superoxide steady-state concentrations. In this study, the levels of Mn-SOD and CuZn-SOD proteins were quantitatively similar in arteries and veins. The activity and amount of EC-SOD protein are significantly higher in human arteries than veins. 22 Taken together with our results, this would suggest that the elevated concentrations of ⅐O 2 Ϫ observed in arteries compared with veins were not a consequence of a reduced capacity for enzymatic removal but rather occurred through increased ⅐O 2 Ϫ production. We also sought to characterize the mechanisms of ⅐O 2 Ϫ production in human IMA and SV. Endothelial NOS activity was inhibited by removal of the endothelium by rubbing and by incubating vessels with L-NAME. This failed to reduce ⅐O 2 Ϫ steady-state concentrations in all patients. The lack of effect of these treatments on ⅐O 2 Ϫ production in the blood vessels of some patients suggests that VSMCs and adventitial fibroblasts were alternative sources of ⅐O 2 Ϫ generation. Inhibition of NAD(P)H oxidase and xanthine oxidase, by incubation of arteries and veins with DPI and ALP, respectively, resulted in similar reductions in basal ⅐O 2 Ϫ steady-state concentrations in both of these tissues. This suggests that both NAD(P)H and xanthine oxidases are sources of ⅐O 2 Ϫ generation in human arteries and veins. Observations from in vitro studies suggest that the activity of xanthine oxidase may be increased in endothelial cells subject to ischemiareperfusion injury. 23 Findings from in vivo human studies suggest that patients with risk factors for CAD also have increased vascular xanthine oxidase-mediated ⅐O 2 Ϫ production, which may contribute to impaired endotheliumdependent vasodilation in these patients. 24 Considered together with our findings, this suggests that xanthine oxidase may be an important source of vascular ⅐O 2 Ϫ production in patients who have CAD.
In the present study, basal ⅐O 2 Ϫ concentrations in IMA were weakly related to patient age. The variation in basal vascular ⅐O 2 Ϫ concentrations observed in this and other human studies 19 and the lack of correlation of ⅐O 2 Ϫ production with some atherosclerotic risk factors, treatment with nitrates, and other therapies may be due to the heterogeneous clinical characteristics of patients with CAD. Such patients have differences in their genetic backgrounds, their atherosclerotic risk factors, their disease duration and severity, and their drug therapy.
We also investigated whether a vasoactive hormone, such as Ang II, could affect ⅐O 2 Ϫ production in human blood vessels. Ang II induced isometric contractions in both arteries and veins but increased ⅐O 2 Ϫ production only in arteries. These effects are unlikely to be due to a reduction in AT 1 receptor expression in veins, because the constrictor effect of Ang II in human saphenous veins, which is known to be AT 1 -dependent, 25 may be greater in SV than IMA. 26 Ang II exerts different effects in distinct vascular beds. 27 One expla- (1 pmol/L, 1 nmol/L, and 1 
؊ Production in IMA After Incubation Periods of 1 and 4 Hours nation for our observations may be that the intracellular mechanisms by which Ang II activates NAD(P)H oxidase may differ in human arteries and veins. In vitro studies in human VSMCs have suggested that Ang II may increase ⅐O 2 Ϫ production in these cells by activation of NAD(P)H oxidase. 28 Our observations may also be substantiated by a report that the pressor effect of intrabrachial artery infusion of Ang II in humans is attenuated by the coinfusion of vitamin C. 29 This study, however, failed to identify a specific Ang II receptor or to evaluate a positive control (ie, another vasoconstrictor, such as norepinephrine).
Experimental studies have demonstrated that the Ang II-mediated increase in ⅐O 2 Ϫ production is of functional importance. The Ang II-stimulated increase in ⅐O 2 Ϫ production contributes to its trophic effect of on rat VSMCs 16 and mesangial cells 30 and also contributes to the pressor effect of this hormone in a hypertensive rat model. 17 We have shown that Ang II increases ⅐O 2 Ϫ production in human arteries by an AT 1 -dependent mechanism. The mechanism of Ang II-mediated increase of ⅐O 2 Ϫ production differs in other species. An AT 1 -dependent Ang II-mediated increase of ⅐O 2 Ϫ production has been reported in the aorta 17 and mesangium 30 of Sprague-Dawley rats and aorta of hypercholesterolemic rabbits. 18 However, the Ang II-induced increase in ⅐O 2 Ϫ production in normocholesterolemic rabbit aortic adventitial fibroblasts is mediated by a non-AT 1 -non-AT 2 -receptor mechanism. 18, 31 The species differences in the mechanism of Ang II-mediated increase in ⅐O 2 Ϫ production emphasize the importance of human investigations, as is the case in the present study.
In conclusion, we have characterized cellular and enzyme sources of ⅐O 2 Ϫ production in human arteries and veins. We have demonstrated that Ang II increases ⅐O 2 Ϫ production at physiological and pharmacological concentrations in human arteries. This effect, which is mediated by NAD(P)H oxidase, is completely inhibited by the AT 1 receptor antagonist losartan. These observations suggest a putative therapeutic role for AT 1 receptor antagonists in reducing oxidative stress in cardiovascular disease. 
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